Point-of-Care Diagnostics Market By Products (Infectious Disease Testing, Glucose Monitoring, Hematology Testing, Pregnancy and Fertility Testing, Urinalysis Testing, Cardiometabolic Monitoring, Tumors or Cancer Marker Testing, Coagulation Monitoring, Cholesterol Testing, Drugs of Abuse Testing), Prescription Mode (Prescription-based Point-of-Care Diagnostics, Over-the-Counter-based Point-of-Care Diagnostics), End-users (Hospitals, Clinics/Physician Office Laboratory, Home Care, Ambulatory Care), and Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025
Global Point-of-Care Diagnostics Market By Products (Infectious Disease Testing, Glucose Monitoring, Hematology Testing, Pregnancy and Fertility Testing, Urinalysis Testing, Cardiometabolic Monitoring, Tumors or Cancer Marker Testing, Coagulation Monitoring, Cholesterol Testing, Drugs of Abuse Testing), Prescription Mode (Prescription-based Point-of-Care Diagnostics, Over-the-Counter-based Point-of-Care Diagnostics), End-users (Hospitals, Clinics/Physician Office Laboratory, Home Care, Ambulatory Care), and Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025
This market research report includes a detailed segmentation of the global point-of-care diagnostics market by products (infectious disease testing, glucose monitoring, hematology testing, pregnancy and fertility testing, urinalysis testing, cardiometabolic monitoring, tumors or cancer marker testing, coagulation monitoring, cholesterol testing, drugs of abuse testing, and others), by prescription mode (prescription-based point-of-care diagnostics and over-the-counter-based point-of-care diagnostics), by end-users (hospitals, clinics/physician office laboratory, home care, and ambulatory care), and by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Point-of-Care Diagnostics Market Research:
Infoholic’s market research report predicts that the global point-of-care diagnostics market will grow at a CAGR of 7.3% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years, and the advancements in technology with the launch of innovative products have increased the adoption of point-of-care diagnostics products. The market is fueled by the increasing prevalence of infectious diseases, upsurge in the incidence of lifestyle diseases, increasing geriatric population, and rising adoption of the technology in emerging countries.
The market continues to grow as point-of-care diagnostics is one of the most widely used techniques for screening, diagnosis, and making a treatment decision. Key market players are focusing on product approvals, new launches, and targeting end-user’s perspective. The market generates significant revenue from the key players operating in this field, and few of them include Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Danaher Corporation, and Siemens Healthineers Inc. (Siemens AG).
According to Infoholic Research analysis, North America accounted for the largest share of the global point-of-care diagnostics market in 2018, and Asia Pacific is expected to grow at a high CAGR during the forecast period. According to a report released by the Centers for Disease Control and Prevention (CDC), in the US alone, more than 100 million adults are now living with diabetes or prediabetes. According to an estimation, in the US, approximately 1,688,780 new cancer cases were diagnosed and 600,920 cancer deaths were reported in 2017. Canada had an estimated 206,200 new cases of cancer and 80,800 deaths from cancer in 2017. Cardiovascular disease (CVD) accounts for approximately 800,000 deaths in the US, and on an average, one person dies from CVD every 40 seconds in the US. Coronary heart disease accounts for the majority of CVD deaths followed by stroke and heart failure. The presence of dominant players in the region, promising reimbursement facilities, availability of hi-tech medical technologies, and growing patient base for lifestyle diseases make North America the dominant shareholder in the market.
By Products:
By Prescription Mode:
By End-users:
By Regions:
Global Point-of-Care Diagnostics Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 7.3% during the forecast period 2019–2025. A lot of new players are concentrating on this market to deliver advanced and innovative products. The increasing adoption of point-of-care diagnostics has resulted in increased approvals, new launches, strategic collaborations, acquisitions, and increased funding. For instance, in February 2019, HemoCue received the FDA approval for its HemoCue Hb 801 System that quantitatively measures hemoglobin in capillary or venous whole blood. In June 2019, Abbott launched its Afinion HbA1c Dx assay available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. Afinion HbA1c Dx assay is the first rapid point-of-care test approved by the FDA to aid healthcare professionals in the diagnosis of diabetes. In March 2019, Group K Diagnostics partnered with the US Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay to detect Zika virus RNA at POC.
Key Vendors:
Key Takeaways:
This market research report includes a detailed segmentation of the global point-of-care diagnostics market by products (infectious disease testing, glucose monitoring, hematology testing, pregnancy and fertility testing, urinalysis testing, cardiometabolic monitoring, tumors or cancer marker testing, coagulation monitoring, cholesterol testing, drugs of abuse testing, and others), by prescription mode (prescription-based point-of-care diagnostics and over-the-counter-based point-of-care diagnostics), by end-users (hospitals, clinics/physician office laboratory, home care, and ambulatory care), and by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Point-of-Care Diagnostics Market Research:
Infoholic’s market research report predicts that the global point-of-care diagnostics market will grow at a CAGR of 7.3% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years, and the advancements in technology with the launch of innovative products have increased the adoption of point-of-care diagnostics products. The market is fueled by the increasing prevalence of infectious diseases, upsurge in the incidence of lifestyle diseases, increasing geriatric population, and rising adoption of the technology in emerging countries.
The market continues to grow as point-of-care diagnostics is one of the most widely used techniques for screening, diagnosis, and making a treatment decision. Key market players are focusing on product approvals, new launches, and targeting end-user’s perspective. The market generates significant revenue from the key players operating in this field, and few of them include Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Danaher Corporation, and Siemens Healthineers Inc. (Siemens AG).
According to Infoholic Research analysis, North America accounted for the largest share of the global point-of-care diagnostics market in 2018, and Asia Pacific is expected to grow at a high CAGR during the forecast period. According to a report released by the Centers for Disease Control and Prevention (CDC), in the US alone, more than 100 million adults are now living with diabetes or prediabetes. According to an estimation, in the US, approximately 1,688,780 new cancer cases were diagnosed and 600,920 cancer deaths were reported in 2017. Canada had an estimated 206,200 new cases of cancer and 80,800 deaths from cancer in 2017. Cardiovascular disease (CVD) accounts for approximately 800,000 deaths in the US, and on an average, one person dies from CVD every 40 seconds in the US. Coronary heart disease accounts for the majority of CVD deaths followed by stroke and heart failure. The presence of dominant players in the region, promising reimbursement facilities, availability of hi-tech medical technologies, and growing patient base for lifestyle diseases make North America the dominant shareholder in the market.
By Products:
- Infectious Disease Testing (influenza testing, HIV testing, hepatitis testing, tuberculosis testing, sexually transmitted diseases testing, healthcare-associated infections testing, respiratory infections testing, others)
- Glucose Monitoring
- Hematology Testing
- Pregnancy and Fertility Testing
- Urinalysis Testing
- Cardiometabolic Monitoring
- Tumors or Cancer Marker Testing
- Coagulation Monitoring
- Cholesterol Testing
- Drugs of Abuse Testing
- Others
By Prescription Mode:
- Prescription-based Point-of-Care Diagnostics
- Over-the-Counter-based Point-of-Care Diagnostics
By End-users:
- Hospitals
- Clinics/Physician Office Laboratory
- Home Care
- Ambulatory Care
- Others
By Regions:
- North America
- Europe
- Asia Pacific
- Rest of the World
Global Point-of-Care Diagnostics Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 7.3% during the forecast period 2019–2025. A lot of new players are concentrating on this market to deliver advanced and innovative products. The increasing adoption of point-of-care diagnostics has resulted in increased approvals, new launches, strategic collaborations, acquisitions, and increased funding. For instance, in February 2019, HemoCue received the FDA approval for its HemoCue Hb 801 System that quantitatively measures hemoglobin in capillary or venous whole blood. In June 2019, Abbott launched its Afinion HbA1c Dx assay available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. Afinion HbA1c Dx assay is the first rapid point-of-care test approved by the FDA to aid healthcare professionals in the diagnosis of diabetes. In March 2019, Group K Diagnostics partnered with the US Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay to detect Zika virus RNA at POC.
Key Vendors:
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Danaher Corporation
- Siemens Healthineers Inc. (Siemens AG)
- Trinity Biotech plc
- Qiagen N.V.
- OraSure Technologies Inc.
- Instrumentation Laboratory (IL)
- Becton Dickinson and Company
- Nova Biomedical
- The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
- The market is moving strongly toward smart devices that are equipped with mobile healthcare (mH). This smart healthcare option is expected to revolutionize personalized healthcare monitoring and management, thus leading the way for next-generation point-of-care testing.
Key Takeaways:
- Understanding the potential market opportunity with precise market size and forecast data.
- Detailed market analysis focusing on the growth of point-of-care diagnostics industry.
- Factors influencing the growth of the point-of-care diagnostics market.
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the point-of-care diagnostics industry in both developed and developing regions.
- Key insights related to major segments of the point-of-care diagnostics market.
- Latest market trend analysis impacting the buying behavior of the consumers.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantages of Point-of-Care Testing
3.3 Disadvantages of Point-of-Care Testing
3.4 Segmented Addressable Market
3.5 Trends in the Point-of-Care Diagnostics Market
3.6 Related Markets
3.6.1 Molecular Diagnostics
3.6.2 Infectious Disease Diagnostics
4 MARKET OUTLOOK
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of infectious disease
5.1.1.2 Growing incidence of lifestyle disease
5.1.1.3 Technological innovations
5.1.1.4 Increasing adoption of point-of-care diagnostics
5.1.2 Opportunities
5.1.2.1 Growth opportunities in emerging markets
5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries
5.1.3 Restraints
5.1.3.1 Stringent approval process
5.1.3.2 Product recalls
5.1.3.3 Unfavorable reimbursement scenario
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 PRODUCT: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Glucose Monitoring
6.3 Infectious Disease Testing
6.3.1 Influenza Testing
6.3.2 HIV Testing
6.3.3 Hepatitis Testing
6.3.4 Tuberculosis Testing
6.3.5 Sexually Transmitted Diseases Testing
6.3.6 Healthcare-associated Infections Testing
6.3.7 Respiratory Infections Testing
6.3.8 Others
6.4 Pregnancy and Fertility Testing
6.5 Hematology Testing
6.6 Cardiometabolic Monitoring
6.7 Urinalysis Testing
6.8 Coagulation Monitoring
6.9 Tumor or Cancer Marker Testing
6.10 Cholesterol Testing
6.11 Drugs of Abuse Testing
6.12 Others
7 PRESCRIPTION MODE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription-based Point-of-Care Diagnostics
7.3 Over the Counter-based Point-of-Care Diagnostics
8 END-USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Clinics/Physician Office Laboratory (POL)
8.4 Home Care
8.5 Ambulatory Care
8.6 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.3.6 Italy
9.3.7 Others
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDORS PROFILE
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Units
11.1.3 Geographic Revenue
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Revenue
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Johnson & Johnson
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 Danaher Corporation
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Revenue
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Siemens Healthineers Inc. (Siemens AG)
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 COMPANIES TO WATCH FOR
12.1 Trinity Biotech plc
12.1.1 Overview
12.2 Qiagen N.V.
12.2.1 Overview
12.3 BioMerieux S.A.
12.3.1 Overview
12.4 OraSure Technologies Inc.
12.4.1 Overview
12.5 Instrumentation Laboratory (A Werfen Company)
12.5.1 Overview
12.6 Becton Dickinson and Company
12.6.1 Overview
12.7 Nova Biomedical
12.7.1 Overview
Annexure
Abbreviations
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantages of Point-of-Care Testing
3.3 Disadvantages of Point-of-Care Testing
3.4 Segmented Addressable Market
3.5 Trends in the Point-of-Care Diagnostics Market
3.6 Related Markets
3.6.1 Molecular Diagnostics
3.6.2 Infectious Disease Diagnostics
4 MARKET OUTLOOK
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of infectious disease
5.1.1.2 Growing incidence of lifestyle disease
5.1.1.3 Technological innovations
5.1.1.4 Increasing adoption of point-of-care diagnostics
5.1.2 Opportunities
5.1.2.1 Growth opportunities in emerging markets
5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries
5.1.3 Restraints
5.1.3.1 Stringent approval process
5.1.3.2 Product recalls
5.1.3.3 Unfavorable reimbursement scenario
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 PRODUCT: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Glucose Monitoring
6.3 Infectious Disease Testing
6.3.1 Influenza Testing
6.3.2 HIV Testing
6.3.3 Hepatitis Testing
6.3.4 Tuberculosis Testing
6.3.5 Sexually Transmitted Diseases Testing
6.3.6 Healthcare-associated Infections Testing
6.3.7 Respiratory Infections Testing
6.3.8 Others
6.4 Pregnancy and Fertility Testing
6.5 Hematology Testing
6.6 Cardiometabolic Monitoring
6.7 Urinalysis Testing
6.8 Coagulation Monitoring
6.9 Tumor or Cancer Marker Testing
6.10 Cholesterol Testing
6.11 Drugs of Abuse Testing
6.12 Others
7 PRESCRIPTION MODE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prescription-based Point-of-Care Diagnostics
7.3 Over the Counter-based Point-of-Care Diagnostics
8 END-USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Clinics/Physician Office Laboratory (POL)
8.4 Home Care
8.5 Ambulatory Care
8.6 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.3.6 Italy
9.3.7 Others
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDORS PROFILE
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Units
11.1.3 Geographic Revenue
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Revenue
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Johnson & Johnson
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 Danaher Corporation
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Revenue
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Siemens Healthineers Inc. (Siemens AG)
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 COMPANIES TO WATCH FOR
12.1 Trinity Biotech plc
12.1.1 Overview
12.2 Qiagen N.V.
12.2.1 Overview
12.3 BioMerieux S.A.
12.3.1 Overview
12.4 OraSure Technologies Inc.
12.4.1 Overview
12.5 Instrumentation Laboratory (A Werfen Company)
12.5.1 Overview
12.6 Becton Dickinson and Company
12.6.1 Overview
12.7 Nova Biomedical
12.7.1 Overview
Annexure
Abbreviations
LIST OF TABLES
TABLE 1 FUNDING SCENARIO
TABLE 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCTS, 2018–2025 ($MILLION)
TABLE 3 GLOBAL INFECTIOUS DISEASE POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2018–2025 ($MILLION)
TABLE 4 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2018–2025 ($MILLION)
TABLE 5 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION)
TABLE 6 EUROPEAN POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 ($MILLION)
TABLE 7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY VENDOR RANKING, 2018
TABLE 8 OTHER PROMINENT VENDORS OF POINT-OF-CARE DIAGNOSTICS MARKET
TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 11 F. HOFFMANN-LA ROCHE: PRODUCT OFFERINGS
TABLE 12 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
TABLE 13 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 14 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 15 DANAHER CORPORATION: PRODUCT OFFERINGS
TABLE 16 DANAHER CORPORATION: RECENT DEVELOPMENTS
TABLE 17 SIEMENS HEALTHINEERS INC.: PRODUCT OFFERINGS
TABLE 18 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
TABLE 19 TRINITY BIOTECH PLC: SNAPSHOT
TABLE 20 TRINITY BIOTECH PLC: RECENT DEVELOPMENTS
TABLE 21 QIAGEN N.V.: SNAPSHOT
TABLE 22 QIAGEN N.V.: RECENT DEVELOPMENTS
TABLE 23 BIOMERIEUX S.A.: SNAPSHOT
TABLE 24 BIOMERIEUX S.A.: RECENT DEVELOPMENTS
TABLE 25 ORASURE TECHNOLOGIES: SNAPSHOT
TABLE 26 ORASURES TECHNOLOGIES: RECENT DEVELOPMENTS
TABLE 27 INSTRUMENTATION LABORATORY: SNAPSHOT
TABLE 28 INSTRUMENTATION LABORATORY: RECENT DEVELOPMENTS
TABLE 29 BECTON DICKINSON AND COMPANY: SNAPSHOT
TABLE 30 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS
TABLE 31 NOVA BIOMEDICAL: SNAPSHOT
TABLE 32 NOVA BIOMEDICAL: RECENT DEVELOPMENTS
TABLE 1 FUNDING SCENARIO
TABLE 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCTS, 2018–2025 ($MILLION)
TABLE 3 GLOBAL INFECTIOUS DISEASE POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2018–2025 ($MILLION)
TABLE 4 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE, 2018–2025 ($MILLION)
TABLE 5 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION)
TABLE 6 EUROPEAN POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 ($MILLION)
TABLE 7 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY VENDOR RANKING, 2018
TABLE 8 OTHER PROMINENT VENDORS OF POINT-OF-CARE DIAGNOSTICS MARKET
TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 11 F. HOFFMANN-LA ROCHE: PRODUCT OFFERINGS
TABLE 12 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
TABLE 13 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 14 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 15 DANAHER CORPORATION: PRODUCT OFFERINGS
TABLE 16 DANAHER CORPORATION: RECENT DEVELOPMENTS
TABLE 17 SIEMENS HEALTHINEERS INC.: PRODUCT OFFERINGS
TABLE 18 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
TABLE 19 TRINITY BIOTECH PLC: SNAPSHOT
TABLE 20 TRINITY BIOTECH PLC: RECENT DEVELOPMENTS
TABLE 21 QIAGEN N.V.: SNAPSHOT
TABLE 22 QIAGEN N.V.: RECENT DEVELOPMENTS
TABLE 23 BIOMERIEUX S.A.: SNAPSHOT
TABLE 24 BIOMERIEUX S.A.: RECENT DEVELOPMENTS
TABLE 25 ORASURE TECHNOLOGIES: SNAPSHOT
TABLE 26 ORASURES TECHNOLOGIES: RECENT DEVELOPMENTS
TABLE 27 INSTRUMENTATION LABORATORY: SNAPSHOT
TABLE 28 INSTRUMENTATION LABORATORY: RECENT DEVELOPMENTS
TABLE 29 BECTON DICKINSON AND COMPANY: SNAPSHOT
TABLE 30 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS
TABLE 31 NOVA BIOMEDICAL: SNAPSHOT
TABLE 32 NOVA BIOMEDICAL: RECENT DEVELOPMENTS
LIST OF FIGURES
CHART 1 RESEARCH METHODOLOGY OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE, 2019–2025 ($MILLION)
CHART 3 SEGMENTATION OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 4 PEST ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 5 PORTER 5 FORCES ON GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 6 DRO – IMPACT ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 7 KEY STAKEHOLDERS
CHART 8 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRODUCT, 2018 V/S 2025 ($)
CHART 9 GLOBAL GLUCOSE MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 10 GLOBAL INFECTIOUS DISEASE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 11 GLOBAL INFLUENZA TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 12 GLOBAL HIV TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 13 GLOBAL HEPATITIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 14 GLOBAL TUBERCULOSIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 15 GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 16 GLOBAL HEALTHCARE-ASSOCIATED INFECTIONS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 17 GLOBAL RESPIRATORY INFECTIONS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 18 GLOBAL OTHERS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 19 GLOBAL PREGNANCY AND FERTILITY TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 20 GLOBAL HEMATOLOGY TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 21 GLOBAL CARDIOMETABOLIC MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 22 GLOBAL URINALYSIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 23 GLOBAL COAGULATION MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 24 GLOBAL TUMOUR OR CANCER MARKER TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 25 GLOBAL CHOLESTEROL TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 26 GLOBAL DRUGS OF ABUSE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 27 GLOBAL OTHERS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 28 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2018 V/S 2025 (%)
CHART 29 GLOBAL PRESCRIPTION-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 30 GLOBAL OTC-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 31 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2018 (%)
CHART 32 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 V/S 2025 (%)
CHART 33 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2019–2025 ($MILLION)
CHART 34 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN EUROPE, 2019–2025 ($MILLION)
CHART 35 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN UNITED KINGDOM, 2019–2025 ($MILLION)
CHART 36 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN GERMANY, 2019–2025 ($MILLION)
CHART 37 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN FRANCE, 2019–2025 ($MILLION)
CHART 38 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN SPAIN, 2019–2025 ($MILLION)
CHART 39 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN ITALY, 2019–2025 ($MILLION)
CHART 40 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN OTHER EUROPEAN COUNTRIES, 2019–2025 ($MILLION)
CHART 41 POINT-OF-CARE DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2019–2025 ($MILLION)
CHART 42 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2019–2025 ($MILLION)
CHART 43 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
CHART 44 ABBOTT LABORATORIES.: BUSINESS UNITS
CHART 45 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
CHART 46 ABBOTT LABORATORIES.: SWOT ANALYSIS
CHART 51 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 52 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 53 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 54 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 55 DANAHER CORPORATION: OVERVIEW SNAPSHOT
CHART 56 DANAHER CORPORATION: BUSINESS UNITS
CHART 57 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
CHART 58 DANAHER CORPORATION: SWOT ANALYSIS
CHART 59 SIEMENS HEALTHINEERS, INC.: OVERVIEW SNAPSHOT
CHART 60 SIEMENS HEALTHINEERS, INC.: BUSINESS UNITS
CHART 61 SIEMENS HEALTHINEERS: GEOGRAPHIC PRESENCE
CHART 62 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
CHART 1 RESEARCH METHODOLOGY OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 2 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET REVENUE, 2019–2025 ($MILLION)
CHART 3 SEGMENTATION OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 4 PEST ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 5 PORTER 5 FORCES ON GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 6 DRO – IMPACT ANALYSIS OF GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET
CHART 7 KEY STAKEHOLDERS
CHART 8 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRODUCT, 2018 V/S 2025 ($)
CHART 9 GLOBAL GLUCOSE MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 10 GLOBAL INFECTIOUS DISEASE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 11 GLOBAL INFLUENZA TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 12 GLOBAL HIV TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 13 GLOBAL HEPATITIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 14 GLOBAL TUBERCULOSIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 15 GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 16 GLOBAL HEALTHCARE-ASSOCIATED INFECTIONS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 17 GLOBAL RESPIRATORY INFECTIONS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 18 GLOBAL OTHERS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 19 GLOBAL PREGNANCY AND FERTILITY TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 20 GLOBAL HEMATOLOGY TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 21 GLOBAL CARDIOMETABOLIC MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 22 GLOBAL URINALYSIS TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 23 GLOBAL COAGULATION MONITORING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 24 GLOBAL TUMOUR OR CANCER MARKER TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 25 GLOBAL CHOLESTEROL TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 26 GLOBAL DRUGS OF ABUSE TESTING MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 27 GLOBAL OTHERS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 28 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY PRESCRIPTION MODE, 2018 V/S 2025 (%)
CHART 29 GLOBAL PRESCRIPTION-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 30 GLOBAL OTC-BASED POINT-OF-CARE DIAGNOSTICS MARKET REVENUE FORECAST, 2019–2025 ($MILLION)
CHART 31 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2018 (%)
CHART 32 GLOBAL POINT-OF-CARE DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 V/S 2025 (%)
CHART 33 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2019–2025 ($MILLION)
CHART 34 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN EUROPE, 2019–2025 ($MILLION)
CHART 35 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN UNITED KINGDOM, 2019–2025 ($MILLION)
CHART 36 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN GERMANY, 2019–2025 ($MILLION)
CHART 37 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN FRANCE, 2019–2025 ($MILLION)
CHART 38 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN SPAIN, 2019–2025 ($MILLION)
CHART 39 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN ITALY, 2019–2025 ($MILLION)
CHART 40 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN OTHER EUROPEAN COUNTRIES, 2019–2025 ($MILLION)
CHART 41 POINT-OF-CARE DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2019–2025 ($MILLION)
CHART 42 POINT-OF-CARE DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2019–2025 ($MILLION)
CHART 43 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
CHART 44 ABBOTT LABORATORIES.: BUSINESS UNITS
CHART 45 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
CHART 46 ABBOTT LABORATORIES.: SWOT ANALYSIS
CHART 51 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 52 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 53 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 54 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 55 DANAHER CORPORATION: OVERVIEW SNAPSHOT
CHART 56 DANAHER CORPORATION: BUSINESS UNITS
CHART 57 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
CHART 58 DANAHER CORPORATION: SWOT ANALYSIS
CHART 59 SIEMENS HEALTHINEERS, INC.: OVERVIEW SNAPSHOT
CHART 60 SIEMENS HEALTHINEERS, INC.: BUSINESS UNITS
CHART 61 SIEMENS HEALTHINEERS: GEOGRAPHIC PRESENCE
CHART 62 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
